David Propper

Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial

Gary Middleton, Paul Silcocks, Trevor F. Cox et al. · The Lancet Oncology · 2014 · 370 citations · Full text

Pancreatic Cancer, Medicine, Immunology +5

Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer

Anthony Maraveyas, Justin S. Waters, Rajarshi Roy et al. · European Journal of Cancer · 2011 · 314 citations · Full text

Pancreatic Cancer, Medicine, Gemcitabine Versus Gemcitabine +4

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

Richard Adams, Angela Meade, Richard H. Wilson et al. · The Lancet Oncology · 2011 · 262 citations · Full text

Phase I and Pharmacokinetic Study of PKC412, an Inhibitor of Protein Kinase C

David Propper, A. McDonald, A. Man et al. · Journal of Clinical Oncology · 2001 · 233 citations

Analysis of colorectal cancers in British Bangladeshi identifies early onset, frequent mucinous histotype and a high prevalence of RBFOX1 deletion

Neel Sengupta, Christopher Yau, Anuratha Sakthianandeswaren et al. · Molecular Cancer · 2013 · 231 citations · Full text